New HIV prevention drug faces drug interaction test
NCT ID NCT07600775
First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 1 time
Summary
This early-stage study looks at how a common tuberculosis drug, rifampin, affects levels of a new HIV prevention medicine called MK-8527. Fourteen adults with latent TB (no active symptoms) will take MK-8527 with and without rifampin. The goal is to see if the two drugs can be used together safely.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- MK-8527 and rifampin
- What this could lead to
- If successful, this study could help determine if MK-8527 can be safely used with rifampin, potentially expanding HIV prevention options for people with latent TB.
- What could go wrong
- This is a very early, small Phase 1 trial with only 14 participants. It focuses on drug levels, not effectiveness or safety, and may not predict real-world outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV PRE-EXPOSURE PROPHYLAXIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a diabetes drug turn back the biological clock in HIV?
- Could a simple blood test ensure the right TB dose for kids?
- Could a simple app help pharmacists stop HIV?
- Scientists probe immune secrets of tuberculosis to find better treatments
- Could One-Time TB pill delivery stop the spread?
- New app could bridge the gap between HIV Self-Testing and PrEP access